{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/sae-dsur-reporting-health-canada”
},
“@id”: “https://www.clinicalstudies.in/sae-dsur-reporting-health-canada”,
“headline”: “SOP for SAE and DSUR Reporting to Health Canada”,
“name”: “SOP for SAE and DSUR Reporting to Health Canada”,
“description”: “Comprehensive SOP defining processes, timelines, and responsibilities for reporting Serious Adverse Events (SAEs), Suspected Unexpected Serious Adverse Reactions (SUSARs), and Development Safety Update Reports (DSURs) to Health Canada.”,
“keywords”: “SAE reporting Health Canada, SUSAR reporting Canada, DSUR submission SOP, expedited safety reporting timelines, pharmacovigilance SOP Canada, SAE case processing, SUSAR compliance Division 5, DSUR regulatory submission Canada, safety reporting sponsor obligations, clinical safety narrative Canada, Health Canada pharmacovigilance requirements, safety reporting workflow SOP, regulatory safety communication Canada, SAE SUSAR PV compliance, annual safety update SOP, DSUR preparation Canada, safety case management SOP, SAE report timelines Canada, inspection readiness PV Canada, pharmacovigilance documentation SOP, safety reporting to regulators Canada, Division 5 safety oversight, SAE report log SOP, DSUR archival requirements, sponsor safety responsibilities”,
“articleSection”: “Standard Operating Procedure”,
“datePublished”: “2025-08-28”,
“dateModified”: “2025-08-28”,
“author”: { “@type”: “Organization”, “name”: “Clinicalstudies.in” },
“publisher”: {
“@type”: “Organization”,
“name”: “Clinicalstudies.in”,
“logo”: { “@type”: “ImageObject”, “url”: “https://www.clinicalstudies.in/logo.png” }
}
}

SAE and DSUR Reporting SOP

Purpose

The purpose of this SOP is to establish clear, regulatory-compliant processes for the identification, assessment, documentation, and reporting of Serious Adverse Events (SAEs), Suspected Unexpected Serious Adverse Reactions (SUSARs), and Development Safety Update Reports (DSURs) to Health Canada. It ensures timely communication, protects subject safety, maintains sponsor obligations under Division 5 of the Food and Drug Regulations, and aligns with ICH-GCP and ICH E2A/E2F guidelines.

Scope

This SOP applies to all interventional clinical trials sponsored or managed by the organization that involve investigational products submitted to Health Canada under a Clinical Trial Application (CTA). It applies to sponsor pharmacovigilance (PV), clinical research, regulatory affairs, investigators, and site staff responsible for adverse event capture, documentation, and reporting.

Responsibilities

• Principal Investigator (PI): Ensures all SAEs are documented and reported to the sponsor within 24 hours of awareness, provides causality assessment, and supports follow-up requests.
• Clinical Research Coordinator (CRC): Assists in SAE data collection, verifies source records, and maintains SAE site files.
• Pharmacovigilance (PV) Team: Performs medical review, causality assessment, prepares case narratives, and submits expedited reports to Health Canada.
• Regulatory Affairs (RA): Coordinates DSUR preparation, ensures timely submission, and files acknowledgments in the TMF.
• Quality Assurance (QA): Audits SAE/SUSAR/DSUR processes and verifies compliance with SOP and regulations.

Accountability

The Sponsor’s Qualified Safety Officer is accountable for ensuring all expedited reports and DSURs are submitted within Health Canada timelines. The Head of Clinical Research is accountable for oversight of compliance across all active trials.

Procedure

1. SAE Reporting Workflow

1. All SAEs must be recorded on the SAE Report Form within 24 hours of investigator awareness.
2. The PI must assess severity, causality, and expectedness based on the Investigator’s Brochure or Reference Safety Information (RSI).
3. Forward SAE documentation to sponsor PV team and REB as required.
4. File source documentation and completed SAE forms in Investigator Site File (ISF).

2. SUSAR Expedited Reporting

1. Fatal or life-threatening SUSARs: Report to Health Canada within 7 calendar days, followed by a complete report within 8 additional days.
2. All other SUSARs: Report within 15 calendar days of sponsor awareness.
3. Submissions must use ICH E2B format through Health Canada electronic gateway with certified translation if required.
4. Maintain SUSAR Submission Log with case ID, subject ID, event, submission date, and acknowledgment.

3. DSUR Submission

1. Prepare annual DSUR covering cumulative safety data, case listings, signal analyses, and benefit-risk evaluations.
2. Submit DSUR in CTD/eCTD format within 60 days of the data lock point.
3. Provide copies to REBs as required by institutional policies.
4. File submission receipts, acknowledgments, and DSUR archival copies in the TMF.

4. Documentation and Record-Keeping

1. Maintain SAE Case Files, SUSAR Submission Logs, and DSUR Submission Logs in TMF.
2. Archive safety documents for minimum of 25 years or until product registration is completed, whichever is longer.
3. Ensure audit trails are complete and ALCOA+ principles are met.

5. Communication with Health Canada

1. All RFIs from Health Canada must be acknowledged within 2 working days.
2. Assign responsibility to PV/RA staff for drafting responses, reviewed by QA prior to submission.
3. Document all communications in the Regulatory Communication Log.

Abbreviations

• SAE: Serious Adverse Event
• SUSAR: Suspected Unexpected Serious Adverse Reaction
• DSUR: Development Safety Update Report
• REB: Research Ethics Board
• PV: Pharmacovigilance
• RA: Regulatory Affairs
• QA: Quality Assurance
• TMF: Trial Master File
• RSI: Reference Safety Information

Documents

1. SAE Reporting Form (Annexure-1)
2. SUSAR Submission Log (Annexure-2)
3. DSUR Submission Log (Annexure-3)

References

• Health Canada — Clinical Trial Guidance
• Food and Drug Regulations, Part C, Division 5
• ICH E2A: Clinical Safety Data Management
• ICH E2F: Development Safety Update Report

Version: 1.0

Approval

Annexures

Annexure-1: SAE Reporting Form

Annexure-2: SUSAR Submission Log

Annexure-3: DSUR Submission Log

Revision History

For more SOPs visit: Pharma SOP.

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.Clinicalstudies.in/SOP-for-Safety-Updates-Annual-Reports-DSUR-PSUR”
},
“headline”: “SOP for Safety Updates in Clinical Trials (Annual Reports, DSUR, PSUR)”,
“description”: “A detailed SOP aligned with ICH E2F, GCP, and WHO guidelines for preparing and submitting annual safety updates including DSUR and PSUR in clinical trials.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for Safety Updates in Clinical Trials (Annual Reports, DSUR, PSUR)

Purpose

The purpose of this SOP is to define the procedures for compiling, reviewing, and submitting safety updates in clinical trials, including Development Safety Update Reports (DSUR), Periodic Safety Update Reports (PSUR), and Annual Safety Reports. These updates ensure ongoing assessment of investigational product safety, regulatory compliance, and protection of trial participants, as per ICH E2F, GCP, and applicable local regulations.

Scope

This SOP applies to all clinical research staff, pharmacovigilance teams, regulatory affairs personnel, and quality assurance officers involved in the preparation, submission, and archiving of annual safety updates. It covers sponsor obligations across multiple regulatory agencies, including FDA, EMA, CDSCO, MHRA, TGA, and WHO.

Responsibilities

• Pharmacovigilance Officer: Collects and analyzes safety data from ongoing trials.
• Regulatory Affairs Manager: Compiles and submits DSUR/PSUR to relevant authorities.
• Principal Investigator: Provides site-specific safety data and narratives.
• Clinical Research Associates (CRAs): Verify accuracy of safety data collected at sites.
• Quality Assurance Officer: Ensures compliance with timelines and content requirements.
• Head of Clinical Research: Final approval before submission.

Accountability

The Head of Pharmacovigilance is accountable for the completeness, accuracy, and timely submission of all safety updates. Non-compliance may result in regulatory action, trial suspension, or safety risks to participants.

Procedure

1. Data Collection and Analysis
Gather adverse event (AE) and serious adverse event (SAE) data from investigators and clinical sites.
Review data from case report forms (CRFs), safety databases, and literature.
Conduct cumulative analysis to identify trends or emerging safety signals.

2. Preparation of DSUR
Follow ICH E2F guidelines for DSUR preparation.
Include global safety data, cumulative summaries, and significant safety issues identified during the reporting year.
Provide benefit-risk evaluation for investigational product.

3. Preparation of PSUR (if applicable)
For marketed products under investigation, prepare PSUR in line with ICH E2C guidelines.
Include post-marketing safety data, spontaneous adverse event reports, and literature findings.

4. Preparation of Annual Safety Reports
Prepare annual safety reports as required by FDA (IND Annual Report) or CDSCO (India).
Provide cumulative safety data, list of SUSARs, and ongoing trial updates.

5. Review and Approval
QA to review draft DSUR/PSUR against regulatory requirements.
Obtain sign-off from Head of Clinical Research and Pharmacovigilance.

6. Submission and Tracking
Submit DSUR/PSUR electronically through regulatory portals (e.g., FDA ESG, EMA CESP).
File proof of submission in Regulatory Communication Log.
Update Safety Update Tracker with submission status and timelines.

7. Archiving
File final DSUR/PSUR in Trial Master File (TMF).
Retain records for at least 5 years post trial completion or as required by local law.

Abbreviations

• SOP: Standard Operating Procedure
• DSUR: Development Safety Update Report
• PSUR: Periodic Safety Update Report
• AE: Adverse Event
• SAE: Serious Adverse Event
• SUSAR: Suspected Unexpected Serious Adverse Reaction
• QA: Quality Assurance
• CRF: Case Report Form
• TMF: Trial Master File

Documents

1. Safety Update Checklist (Annexure-1)
2. Safety Update Tracker (Annexure-2)
3. Regulatory Communication Log (Annexure-3)

References

• ICH E2F – Development Safety Update Report Guidelines
• ICH E2C – Periodic Safety Update Report Guidelines
• ICH E6(R2) Good Clinical Practice
• US FDA IND Annual Reporting Requirements
• EMA and WHO Pharmacovigilance Guidelines

Version: 1.0

Approval Section

Annexures

Annexure-1: Safety Update Checklist

Annexure-2: Safety Update Tracker

Annexure-3: Regulatory Communication Log

Revision History

For more SOPs visit: Pharma SOP